Drug Approval | May 25, 2026
Datroway wins US nod in aggressive breast cancer subtype
Clearance marks major shift beyond chemotherapy
Clearance marks major shift beyond chemotherapy
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Dr Mohit Bhandari remotely conducted a complex robotic gastrojejunostomy from Perth using the indigenous SSI Mantra Surgical Robotic System
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
